Of relevance, we demonstrate that the absence of CD28 provides a functional advantage to Ag-experienced (ICOS+, CD137+, CD11ahigh) PD1+CD8+ T cells in the setting of peripheral blood of cancer patients. This evidence concerns the gene CD28 and cancer.